Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioInvent International AB

https://www.bioinvent.com/

Latest From BioInvent International AB

BioInvent Banks $116m As NHL Drug Nears Phase III

Following positive interim results from a Phase I/IIa trial of BI-1206 in combination with Roche's Rituxan, BioInvent has raised a significant sum to push the non-Hodgkin's lymphoma drug towards late-stage development.

Financing Cancer

Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease

Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.

Scrip Asks Artificial Intelligence

Asia Deal Watch: CStone Partners With LegoChem On Novel ADC Candidate

Plus deals involving Lilly/Daiichi Sankyo, Humianigen/KPM Tech, Telix/China Grand, Appili/Fujifilm, BioInvent/CASI, Osotec/Adel, Neumentum/Nuance, Takeda/HemoShear and Quantum Genomics/Qilu.

Deals Business Strategies

Drug-Coated Balloon For Urethral Strictures Debuts In Europe, Version For BPH Planned

Urotronic set to complete a $20m series C, bringing its total funding to $61m for the development of drug-eluting balloon-based urology products.

Drug Delivery Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Bioinvent Finans AB
UsernamePublicRestriction

Register